Clinical trial
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients…
NCT00372567 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00372567 |
|---|---|
| Title | Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors |
| Official title | A Phase IIIB, Randomized, Active Controlled Open-Label Study Of Sunitinib (Sutent) 37.5 Mg Daily Vs Imatinib Mesylate 800 Mg Daily In The Treatment Of Patients With Gastrointestinal Stromal Tumors (GIST) Who Have Had Progressive Disease While On 400 Mg Daily Of Imatinib |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumor |
| Intervention type | Drug |
| Interventions | sunitinib malate, imatinib mesylate |
| Enrollment | 69 |
| Start date | Jun 1, 2007 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Sep 7, 2006 |
| Last update posted | Mar 17, 2011 |
| Countries | Germany, Hong Kong, Italy, South Korea, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: